- Home
- SITC vs PHVS Comparison
SITC vs PHVS Comparison
Compare SITC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- PHVS
- Stock Information
- Founded
- SITC 1965
- PHVS 2015
- Country
- SITC United States
- PHVS Netherlands
- Employees
- SITC N/A
- PHVS N/A
- Industry
- SITC Real Estate Investment Trusts
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- SITC Real Estate
- PHVS Health Care
- Exchange
- SITC Nasdaq
- PHVS Nasdaq
- Market Cap
- SITC 786.5M
- PHVS 894.8M
- IPO Year
- SITC 1993
- PHVS 2021
- Fundamental
- Price
- SITC $14.61
- PHVS $16.49
- Analyst Decision
- SITC Hold
- PHVS Strong Buy
- Analyst Count
- SITC 9
- PHVS 5
- Target Price
- SITC $38.78
- PHVS $41.60
- AVG Volume (30 Days)
- SITC 683.6K
- PHVS 39.6K
- Earning Date
- SITC 02-27-2025
- PHVS 04-09-2025
- Dividend Yield
- SITC 7.15%
- PHVS N/A
- EPS Growth
- SITC 757.51
- PHVS N/A
- EPS
- SITC 13.71
- PHVS N/A
- Revenue
- SITC $451,683,000.00
- PHVS N/A
- Revenue This Year
- SITC N/A
- PHVS N/A
- Revenue Next Year
- SITC N/A
- PHVS N/A
- P/E Ratio
- SITC $1.06
- PHVS N/A
- Revenue Growth
- SITC N/A
- PHVS N/A
- 52 Week Low
- SITC $14.47
- PHVS $15.21
- 52 Week High
- SITC $64.44
- PHVS $28.40
- Technical
- Relative Strength Index (RSI)
- SITC 40.76
- PHVS 36.48
- Support Level
- SITC $14.53
- PHVS $17.01
- Resistance Level
- SITC $14.84
- PHVS $17.94
- Average True Range (ATR)
- SITC 0.35
- PHVS 0.71
- MACD
- SITC -0.02
- PHVS -0.09
- Stochastic Oscillator
- SITC 17.18
- PHVS 17.44
About SITC SITE Centers Corp.
SITE Centers Corp is a United States-based self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.